NewAmsterdam Pharma to Participate in Upcoming Medical Meeting and Investor Conferences in September

Core Insights - NewAmsterdam Pharma is set to present additional pooled safety and efficacy data from the pivotal Phase 3 BROADWAY and BROOKLYN trials at the European Society of Cardiology Congress (ESC) from August 29 to September 1, 2025 [1] - The company is focused on developing oral, non-statin medicines for patients at risk of cardiovascular disease with elevated low-density lipoprotein cholesterol [1][5] Presentation Details - The first presentation titled "Efficacy of obicetrapib across the spectrum of background lipid lowering therapies-pooled analyses of the Broadway and Brooklyn randomized trials" will take place on August 29, 2025, at 10:10 am CEST [2] - A second presentation titled "Obicetrapib and cardiovascular events" is scheduled for September 1, 2025, at 9:00 am CEST [3] Upcoming Investor Conferences - NewAmsterdam management will participate in several investor conferences, including: - Citi's 2025 Biopharma Back to School Summit on September 3, 2025, at 2:30 pm ET in Boston, MA [4] - Cantor Global Healthcare Conference on September 4, 2025, at 2:45 pm ET in New York, NY [4] - Wells Fargo Healthcare Conference on September 5, 2025, at 10:15 am ET in Boston, MA [4] - Live webcasts of these presentations will be available on the company's investor relations website [4]